|Articles|March 1, 2007
Genentech letter warns of stroke risk with ranibizumab
South San Francisco-Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























